7 completed, 1 unknown. 7 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 4 | 1 | Unknown 1 |
Follow obiltoxaximab: new trials by email Literature Review of obiltoxaximab trials Research Report on obiltoxaximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis Collection of samples, Obiltoxaximab - Infection, Bacterial, Anthrax | Phase 4 | Unknown | Elusys Therapeutics | 100 | 2023-12-01 | 2023-07-14 |
| Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers ETI-204, Ciprofloxacin - Inhalational Anthrax | Phase 1 | Completed | Elusys Therapeutics | 40 | 2013-10-29 | 2019-04-16 |
| Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers ETI-204, Placebo - Inhalational Anthrax | Phase 1 | Completed | Elusys Therapeutics | 36 | 2013-07-26 | 2019-05-06 |
| Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers ETI-204, Placebo - Inhalational Anthrax | Phase 1 | Completed | Elusys Therapeutics | 70 | 2013-07-23 | 2019-05-14 |
| Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers ETI-204, Placebo - Inhalational Anthrax | Phase 1 | Completed | Elusys Therapeutics | 280 | 2013-07-09 | 2019-04-08 |
| Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers ETI-204, "Anthim", placebo - Anthrax | Phase 1 | Completed | Elusys Therapeutics | 108 | 2011-10-01 | 2017-11-14 |
| Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers ETI-204, "Anthim", placebo - Healthy Volunteers | Phase 1 | Completed | Elusys Therapeutics | 45 | 2009-02-01 | 2017-11-14 |
| Monoclonal Antibody for Treatment of Inhalation Anthrax Ciprofloxacin 500 mg, ETI-204 (Anthim) - Bacillus Anthracis (Anthrax) | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2005-10-01 | 2010-08-27 |
Anthrax (5) · Inhalation anthrax (4) · Bacterial Infections (1)
Elusys Therapeutics (7) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (7)
Alex King, MD (2) · David Mathews, MD (2) · Debra Mandarino, MD (1) · Eleanor A Lisbon, M.D., M.P.H (1) · Glen Apseloff, MD (1) · H. Frank Farmer, PhD, MD (1) · Jolene Berg, MD (1) · Lori Sieboldt, MD (1) · Timothy S. Leach, MD, MPH (1)